JP2025114555A5 - - Google Patents

Info

Publication number
JP2025114555A5
JP2025114555A5 JP2025062046A JP2025062046A JP2025114555A5 JP 2025114555 A5 JP2025114555 A5 JP 2025114555A5 JP 2025062046 A JP2025062046 A JP 2025062046A JP 2025062046 A JP2025062046 A JP 2025062046A JP 2025114555 A5 JP2025114555 A5 JP 2025114555A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
formula
sbebcd
structural formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025062046A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025114555A (ja
Filing date
Publication date
Priority claimed from PCT/US2020/032941 external-priority patent/WO2020232274A1/en
Application filed filed Critical
Publication of JP2025114555A publication Critical patent/JP2025114555A/ja
Publication of JP2025114555A5 publication Critical patent/JP2025114555A5/ja
Pending legal-status Critical Current

Links

JP2025062046A 2019-05-15 2025-04-03 皮下注射のためのケタミン製剤 Pending JP2025114555A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962848420P 2019-05-15 2019-05-15
US62/848,420 2019-05-15
PCT/US2020/032941 WO2020232274A1 (en) 2019-05-15 2020-05-14 Ketamine formulation for subcutaneous injection
JP2021568611A JP2022533971A (ja) 2019-05-15 2020-05-14 皮下注射のためのケタミン製剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021568611A Division JP2022533971A (ja) 2019-05-15 2020-05-14 皮下注射のためのケタミン製剤

Publications (2)

Publication Number Publication Date
JP2025114555A JP2025114555A (ja) 2025-08-05
JP2025114555A5 true JP2025114555A5 (enExample) 2025-10-28

Family

ID=73230954

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021568611A Pending JP2022533971A (ja) 2019-05-15 2020-05-14 皮下注射のためのケタミン製剤
JP2025062046A Pending JP2025114555A (ja) 2019-05-15 2025-04-03 皮下注射のためのケタミン製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021568611A Pending JP2022533971A (ja) 2019-05-15 2020-05-14 皮下注射のためのケタミン製剤

Country Status (6)

Country Link
US (2) US10973780B2 (enExample)
EP (1) EP3968979A4 (enExample)
JP (2) JP2022533971A (enExample)
CN (2) CN114126596A (enExample)
CA (1) CA3140046A1 (enExample)
WO (1) WO2020232274A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE056378T2 (hu) 2013-09-13 2022-02-28 Univ Chiba Nat Univ Corp R-Ketamin és sójának alkalmazása gyógyszerekként
US11980595B2 (en) 2018-02-15 2024-05-14 National University Corporation Chiba University Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
WO2019213551A1 (en) 2018-05-04 2019-11-07 Perception Neuroscience, Inc. Methods of treating substance abuse
EP3968979A4 (en) * 2019-05-15 2023-03-01 Bexson Biomedical, Inc. KETAMINE FORMULATION FOR SUBCUTANEOUS INJECTION
US12233165B2 (en) 2020-08-18 2025-02-25 Oakwood Laboratories, Llc Microsphere formulations comprising ketamine and methods for making and using the same
JP2023551145A (ja) 2020-11-18 2023-12-07 ベクソン バイオメディカル，インク． 医薬化合物の錯化剤塩製剤
WO2022109050A1 (en) * 2020-11-18 2022-05-27 Bexson Biomedical, Inc. Complexing agent salt formulations of pharmaceutical compounds
EP4493155A1 (en) * 2022-03-14 2025-01-22 Perception Neuroscience, Inc. Pharmaceutical formulations of r-ketamine
WO2023225113A1 (en) * 2022-05-18 2023-11-23 Bexson Biomedical, Inc. Complexing agent salt formulations of pharmaceutical compounds at low stoichiometric ratios
IN202221054235A (enExample) 2022-09-22 2023-11-03
WO2024171074A1 (en) * 2023-02-15 2024-08-22 Clearmind Medicine Inc. Compositions comprising ketamine, optionally in combination with n-acylethanolamines, and uses thereof
US12005035B1 (en) * 2023-08-14 2024-06-11 Daniel C. Javitt Compositions and methods for treatment of chronic pain and depression

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5352683A (en) * 1993-03-05 1994-10-04 Virginia Commonwealth University Medical College Of Virginia Method for the treatment of chronic pain
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
CA2230690C (en) * 1995-08-30 2008-12-23 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
ATE367828T1 (de) * 1998-04-03 2007-08-15 Novartis Vaccines & Diagnostic Igf-enthaltende injizierbare formulierungen enthaltend succinate als puffermittel
CN1172908C (zh) 1999-12-10 2004-10-27 中国科学院上海药物研究所 N-取代苄基或苯基芳香磺酰胺化合物及其用途
EP1383445A4 (en) * 2001-03-20 2005-04-13 Cydex Inc FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
AR046769A1 (es) * 2003-12-22 2005-12-21 Schering Corp Composiciones farmaceuticas
CN1939298A (zh) 2005-09-29 2007-04-04 中国科学院上海药物研究所 硫酸舒欣啶固体和靶向制剂及其制备方法
AU2007229866A1 (en) 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
BRPI0809843A2 (pt) * 2007-04-26 2014-09-23 Auspex Pharmaceuticals Inc "composto, composição farmacêutica e uso de um composto"
WO2013056229A1 (en) * 2011-10-14 2013-04-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services The use of (2r, 6r)-hydroxynorketamine, (s)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (r,s)- ketamine in the treatment of depression and neuropathic pain
EP2830604A4 (en) * 2012-03-30 2015-08-19 Gen Hospital Corp COMPOSITIONS WITH SCOPOLAMINE AND KETAMINE FOR THE TREATMENT OF DEPRESSIONS
US20130296437A1 (en) 2012-05-04 2013-11-07 E-Therapeutics Plc Treatment of Depression
US10124940B2 (en) 2012-09-11 2018-11-13 Zolo Solutions, Inc. Systems, methods, and devices for dispensing one or more substances
EP3442940A1 (en) * 2016-04-11 2019-02-20 Clexio Biosciences Ltd. Deuterated ketamine derivatives
EP3968979A4 (en) * 2019-05-15 2023-03-01 Bexson Biomedical, Inc. KETAMINE FORMULATION FOR SUBCUTANEOUS INJECTION

Similar Documents

Publication Publication Date Title
JP2025114555A5 (enExample)
JP2022533971A5 (enExample)
KR810000900B1 (ko) 항생물질 조성제의 안정화 방법
JP2025016462A (ja) 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
JPS6146455B2 (enExample)
JP7738696B2 (ja) フロセミドの濃縮液体医薬製剤及びそれを投与する方法
WO1999011252A2 (en) N,n-bis (phenylcarbamoylmethyl) dimethylammonium chloride and derivatives in the treatment of pain
CN114630669B (zh) 稳定的医药组合物
JP2001522888A (ja) 麻酔用製剤
US20050004221A1 (en) Intrathecal gabapentin compositions
JP2023518299A5 (enExample)
US5118698A (en) Pharmaceutical preparations
JP2025507308A5 (enExample)
CN1649589A (zh) 用艾芬地尔治疗疼痛的方法
JP2812683B2 (ja) 持続性を有するモルヒネ直腸投与製剤
EP1682149B1 (en) Injectable gabapentin compositions
US2919228A (en) Parenteral composition to reduce duration of local anesthesia
TW202523320A (zh) 用於皮下投與之包含普拉曲沙之組合物及其使用方法
HK40074840B (zh) 稳定的医药组合物
JPWO2024171859A5 (ja) ｐＨ応答性リン脂質、リン脂質塩、脂質粒子、アルコール溶液、医薬、及び脂質粒子の製造方法
RU2578433C1 (ru) Противотуберкулёзная фармацевтическая композиция для парентерального применения в дозировках малого объема
JP2020019757A (ja) パロノセトロン含有液体組成物
CN101073552A (zh) 盐酸椎双净鼻用凝胶喷雾剂及其应用
US20040019075A1 (en) New formulation for the parenteral application of crobenetine
RU2024116274A (ru) Кристаллическая форма гемитартратной соли (r)-2-(трет-бутиламино)-1-(5-фторпиридин-3-ил)-этан-1-ола для лечения гипергликемии и диабета 2-го типа